Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents

Size: px
Start display at page:

Download "Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents"

Transcription

1 BUMC Proceedings 1999;12: Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human monoclonal antibodies have been introduced to the market with approval for use in the prevention of acute renal transplant rejection. The following is a review of these agents and an analysis of their potential usefulness in antirejection regimens. BACKGROUND The development of immunosuppressive agents with less toxicity and more specificity has led researchers to explore the role of interleukin-2 (IL-2) in the immunosuppression cascade. The IL-2 receptor is composed of at least 3 subunits. One subunit, the a chain, named the Tac antigen, is predominantly expressed on activated T cells. Interleukin-2 facilitates the proliferation of alloantigen-activated T-cell clones by interacting with the IL-2 receptor, a critical step in the process of allograft rejection. For this reason, monoclonal antibody development was directed at this portion of the receptor and was called anti-tac. Agents such as cyclosporine and tacrolimus target different sites along the immunosuppression cascade. It is thought that the IL-2 receptorblocking monoclonal antibody will produce a synergistic effect when given in addition to current 3-drug regimens (i.e., cyclosporine or tacrolimus plus steroids plus azathioprine or mycophenolate mofetil) (1 3). Muromonab-CD3 (Orthoclone OKT3, Ortho Biotech, Inc., Raritan, N.J.) was the first monoclonal anti T-cell preparation used to produce immunosuppression. This product, developed with murine hybridoma techniques, has been used in both the prevention and the treatment of acute rejection after renal and liver transplantation (4). Typically, transplant centers reserve the use of muromonab-cd3 for situations in which 1) induction of immunosuppression using cyclosporine or tacrolimus as the primary immunosuppressive agent is contraindicated due to poor renal function, or 2) it is used as rescue therapy in steroid-resistant rejection. Both indications are suitable for kidney or liver transplant recipients. The use of murine anti-tac monoclonal antibodies has been limited, however, for several reasons. Eighty percent of recipients develop antibodies to the mouse immunoglobulin, rendering muromonab-cd3 ineffective with repeat exposure. Side effects, including the risk of anaphylaxis, are high with this product (5). Theoretically, these problems could be resolved with a more humanized product. Another disadvantage of muromonab-cd3 is its short half-life. Daily administration is required, increasing costs associated with drug acquisition, premedication, nursing labor, and lengthened hospital stays.

2 BASILIXIMAB Basiliximab (Simulect, Novartis Pharmaceuticals Corporation, East Hanover, N.J.) is a chimeric IgG1 mouse/human monoclonal antibody that binds to the chain of the IL-2 receptor, thus blocking IL-2 mediated activation of T lymphocytes. The half-life of this product is approximately 7 days. The frequency and types of side effects seen with basiliximab in the clinical trials did not differ from those observed in the placebo group. Two small studies assessed the pharmacodynamic and pharmacokinetic properties of the drug in renal transplantation (5, 6). In a larger, multicenter (European/Canadian) trial designed to assess the effects of prophylactic treatment with basiliximab, 376 patients were randomly assigned to receive either 2 doses of basiliximab (n = 190) or placebo (n = 186). Both groups received cyclosporine microemulsion (Neoral, Novartis Pharmaceuticals Corporation, East Hanover, N.J.) and steroids, according to the institution s established regimen. All patients received primary renal transplantation from a donor with at least 1 human leukocyte antigen class I or class II mismatch. Patients in the treatment group were given basiliximab (20 mg) infusion 2 hours prior to transplant. A second infusion of basiliximab (20 mg) was administered on day 4. Patients assigned to the control group received the same regimen with placebo infusions. Rejection was defined as a rejection episode confirmed by final clinical diagnosis and for which therapy was given. Confirmation and grading of rejection episodes were determined through biopsy sampling, when technically feasible. Patients who experienced episodes of acute rejection were treated with steroid boluses according to institutional standards. Patients with steroid-resistant rejection were treated with site-specific drug regimens (7). Data on the rates of rejection, the prevalence of biopsy-confirmed episodes of rejection, the number of steroid-resistant first rejection episodes treated with antibody therapy, as well as graft survival, are presented in Table 1. Noteworthy is the difference in antibody therapy requirements due to episodes of steroid-resistant rejection (basiliximab, n = 19; placebo, n = 43; P < 0.001). Current treatment for this type of rejection with muromonab-cd3 adds an additional $7200 to the cost of therapy. One also should note that, although the incidence of acute rejection was reduced in patients receiving basiliximab, at 12 months differences in overall graft and patient survival rates between the 2 groups were not statistically significant (7). The acquisition cost for a 20-mg vial of basiliximab at our institution is $ The cost for the full course of basiliximab therapy, when given according to the trial design and corresponding

3 manufacturer s recommendations, is $ DACLIZUMAB Daclizumab (Zenapax, Roche Pharmaceuticals, Nutley, N.J.) is a molecularly engineered human anti IL-2 receptor antibody. The drug has a long half-life of about 20 days. Genetic engineering is thought to have produced a product with high affinity and high specificity for the target receptor. In the clinical trials, there were no differences in side effects between the treatment group and the placebo group (8). Two major trials have been reported. Results of these trials are compiled in Tables 2 and 3. Trial #1 was a randomized, double-blind, placebo-controlled phase III study that was conducted in Europe, Canada, and Australia. Patients receiving a first cadaveric renal transplant were enrolled in the study, and all patients were treated with cyclosporine and corticosteroids. A total of 5 doses of daclizumab was given (1 mg/kg; maximum, 100 mg per dose) to those randomized to the treatment arm (n = 141). The first dose was administered on the day of transplantation. The 4 remaining doses were then given every 2 weeks. Placebo (n = 134) was given on the same schedule. Primary efficacy was based on biopsy-proven acute rejection that occurred within the first 6 months of transplantation, although some patients were considered to have presumptive rejection if treated for a rejection episode. Secondary efficacy assessment compared patient and graft survival at 6 months and 12 months after transplantation. Time from transplantation to the first episode of rejection and the total number of episodes of acute rejection also were examined in this assessment (9, 10).

4 The incidence of biopsy-proven rejection, as well as presumptive acute rejection, was lower in the treatment arm. Similarly, the delay to the first episode of rejection was greater for the treatment group. Graft survival rates, however, were not statistically significant between the 2 groups (9, 10). The second study with daclizumab, trial #2, involved triple-drug therapy regimens (cyclosporine, azathioprine, and prednisone). This was a randomized, double-blind, placebo-controlled, multicenter trial (USA, Canada, Sweden) designed to compare the efficacy of daclizumab with placebo for the prevention of acute rejection in primary renal transplantation. Dosing regimens were consistent with the dual-therapy trial (trial #1), with similar primary and secondary endpoint targets. Results of the study are shown in Table 3 (11). The results of this study were similar to those of the trial #1 study. Statistically significant differences were seen in the number of episodes of acute rejection and the time between transplantation and that first rejection episode. The difference in graft survival rates for treatment and placebo groups was not significant (11). Daclizumab is available as a 25-mg/5-mL vial. Its cost at our institution is $ The cost for each dose of daclizumab is $ , and the full course of therapy costs $ when given according to study design and manufacturer s recommendations. SUMMARY In previous studies, renal transplant recipients who experienced delayed (versus immediate) episodes of acute rejection had a better overall likelihood of graft survival. Impressive data from the clinical studies assessing basiliximab and daclizumab confirm statistically significant reductions in the time from transplantation to the time to the first rejection episode. This was not, however, carried over to the data for graft survival at 12 months for either agent. A noteworthy finding in the basiliximab trials was a reduction in the incidence of steroid-resistant rejection, which could potentially reduce the need for, and subsequent cost of, muromonab-cd3 therapy. No studies have reported the results of these therapies in other solid organ transplant patient populations or bone marrow transplant recipients. Currently, muromonab-cd3 is the only formulary agent. If either basiliximab or daclizumab is obtained, data will be collected to evaluate parameters similar to those in the trials cited. These data would be available for future formulary decisions for this class of medications. References 1. Sondel PM: Transplantation. In Graziano FM, Lemanske RF, eds: Clinical Immunology. Baltimore: Williams & Wilkins, 1989: Ascher NL: Interleukin-2 receptor antibody therapy. Liver Transpl Surg 1997;3: Kovarik J, Breidenbach, T, Gerbeau C, Korn A, Schmidt AG, Nashan B: Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998;64: Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castaigne JP, Moore R, Sweny P: Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody

5 used in cadaveric renal transplantation. Transplantation 1995;60: New monoclonal antibodies to prevent transplant rejection. Med Lett Drug Ther 1998;40: Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Gerbeau C, Schmidt AG, Soulillou JP: Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64: Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997;350: Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S: A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997;63: Charpentier B, Thervet E: Placebo-controlled study of a humanized anti-tac monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation. Transplant Proc 1998;30: Vincenti F, Nashan B, Light S, for the Double Therapy and the Triple Therapy Study Groups: Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998;30: Vincenti F, Kirkman R, Light S, Bumgardner G, Psecovitz, M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:

ABSTRACT Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive

ABSTRACT Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive INTERLEUKIN-2 RECEPTOR BLOCKADE WITH TO PREVENT REJECTION IN RENAL TRANSPLANTATION INTERLEUKIN-2 RECEPTOR BLOCKADE WITH TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION FLAVIO VINCENTI, M.D., ROBERT

More information

Low toxicity immunosuppressive protocols in renal transplantation. Ron Shapiro

Low toxicity immunosuppressive protocols in renal transplantation. Ron Shapiro LECTURE Low toxicity immunosuppressive protocols in renal transplantation Ron Shapiro Department of Surgery, Director, Renal Transplantation, Thomas E. Starzl, Transplantation Institute University of Pittsburgh,

More information

Date: 23 June Context and policy issues:

Date: 23 June Context and policy issues: Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

This study is currently recruiting participants.

This study is currently recruiting participants. A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting

More information

Emerging Drug List EVEROLIMUS

Emerging Drug List EVEROLIMUS Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Simulect 20 mg powder and solvent for solution for injection or infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial

More information

The addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY

The addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin

More information

Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham

Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting

More information

Immunosuppression: evolution in practice and trends,

Immunosuppression: evolution in practice and trends, American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar

More information

NEW ZEALAND DATA SHEET SIMULECT Basiliximab 20 mg Injection

NEW ZEALAND DATA SHEET SIMULECT Basiliximab 20 mg Injection NEW ZEALAND DATA SHEET SIMULECT Basiliximab 20 mg Injection Description and composition One vial of Simulect 20 mg contains 20 mg basiliximab. An ampoule containing 5 ml water for injection is supplied

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

Interleukin 2 receptor antagonists for kidney transplant recipients (Review)

Interleukin 2 receptor antagonists for kidney transplant recipients (Review) Interleukin 2 receptor antagonists for kidney transplant recipients (Review) Webster AC, Playford EG, Higgins GY, Chapman JR, Craig JC This is a reprint of a Cochrane review, prepared and maintained by

More information

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin

More information

Received: 14 July 2016, Revised and Accepted: 23 July 2016

Received: 14 July 2016, Revised and Accepted: 23 July 2016 Vol 9, Issue 6, 2016 Online - 2455-3891 Print - 0974-2441 Research Article COMPARISON OF INDUCTION THERAPY USING ANTI-THYMOCYTE GLOBULIN AND USING BASILIXIMAB FOR LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS:

More information

Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct

Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus

More information

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH

More information

Basiliximab in pediatric liver transplantation: A pharmacokinetic-derived dosing algorithm

Basiliximab in pediatric liver transplantation: A pharmacokinetic-derived dosing algorithm Pediatr Transplantation 2002: 6: 224 230 Printed in UK. All rights reserved Copyright # 2002 Blackwell Munksgaard Pediatric Transplantation ISSN 1397-3142 Basiliximab in pediatric liver transplantation:

More information

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis

More information

General Introduction. 1 general introduction 13

General Introduction. 1 general introduction 13 General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately

More information

PREVENTION OF REJECTION IN CARDIAC TRANSPLANTATION BY BLOCKADE OF THE INTERLEUKIN-2 RECEPTOR

PREVENTION OF REJECTION IN CARDIAC TRANSPLANTATION BY BLOCKADE OF THE INTERLEUKIN-2 RECEPTOR PREVENTION OF REJECTION IN CARDIAC TRANSPLANTATION BY BLOCKADE OF THE INTERLEUKIN-2 RECEPTOR WITH A MONOCLONAL ANTIBODY AINAT BENIAMINOVITZ, M.D., SILVIU ITESCU, M.D., KATHERINE LIETZ, M.D., MARY DONOVAN,

More information

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study: An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status

More information

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section

More information

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery

More information

Tolerance Induction in Transplantation

Tolerance Induction in Transplantation Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent

More information

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi

More information

Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies

Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific

More information

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was

More information

Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia

Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department

More information

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;

More information

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated

More information

Transplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005

Transplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 Immunosuppressive e therapy for kidney transplant in children and young people Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta482 NICE 2018. All rights reserved. Subject

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party

More information

Transplantation in Australia and New Zealand

Transplantation in Australia and New Zealand Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia

More information

Lothar Bernd Zimmerhackl

Lothar Bernd Zimmerhackl What works in current paediatric practice of off-label dose adjustment of adult doses? Lothar Bernd Zimmerhackl Medical University Innsbruck Austria AGAH Workshop: Pediatric Investigation Plan. Bonn 13-14.1.

More information

Nephrology Dialysis Transplantation

Nephrology Dialysis Transplantation Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.

More information

Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial

Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): a randomised trial Journal club Feb 2014 Background and Rationale Despite substantial

More information

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961 CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department

More information

Organ rejection is one of the serious

Organ rejection is one of the serious Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.

More information

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) 3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day

More information

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids

More information

Summary of Results for Laypersons

Summary of Results for Laypersons What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive

More information

Chapter VII. Renal Transplantation: Access and Outcomes. Methods. Key Words: Gender in transplantation

Chapter VII. Renal Transplantation: Access and Outcomes. Methods. Key Words: Gender in transplantation Annual Data Report Renal Transplantation: Access and Outcomes Chapter VII Renal Transplantation: Access and Outcomes D Key Words: Cadaveric renal transplants Living related renal transplants Transplant

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Cyclosporine (CsA) dose adjustments based on. C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective

Cyclosporine (CsA) dose adjustments based on. C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective REVIEW C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective Federico Villamil 1 and Stephen Pollard 2 Adjusting cyclosporine (CsA) dose based on blood concentration

More information

Steroid Minimization: Great Idea or Silly Move?

Steroid Minimization: Great Idea or Silly Move? Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,

More information

Alemtuzumab Induction in Renal Transplantation

Alemtuzumab Induction in Renal Transplantation original article Induction in Renal Transplantation Michael J. Hanaway, M.D., E. Steve Woodle, M.D., Shamkant Mulgaonkar, M.D., V. Ram Peddi, M.D., Dixon B. Kaufman, M.D., Ph.D., M. Roy First, M.D., Richard

More information

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa

More information

S tefan Vítko 1 and Marek Ferkl 2. original article

S tefan Vítko 1 and Marek Ferkl 2. original article http://www.kidney-international.org & 2010 International Society of Nephrology Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of and capsules in

More information

HLA and Non-HLA Antibodies in Transplantation and their Management

HLA and Non-HLA Antibodies in Transplantation and their Management HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes

More information

Clinical decisions regarding immunosuppressive

Clinical decisions regarding immunosuppressive PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens

More information

Innovation In Transplantation:

Innovation In Transplantation: Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were

More information

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest

More information

OBJECTIVES. Phases of Transplantation and Immunosuppression

OBJECTIVES. Phases of Transplantation and Immunosuppression Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and

More information

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN

More information

Changes in peripheral blood Th1 and Th2 cells in rat liver transplantation under different immune statuses

Changes in peripheral blood Th1 and Th2 cells in rat liver transplantation under different immune statuses Changes in peripheral blood Th1 and Th2 cells in rat liver transplantation under different immune statuses Z.-L. Yang, K. Cheng, H.G. Sun, W.W. Zou and M.M. Wu Department of Thyroid and Breast Surgery,

More information

A Tolerance Approach to the Transplantation of Vascularized Tissues

A Tolerance Approach to the Transplantation of Vascularized Tissues A Tolerance Approach to the Transplantation of Vascularized Tissues The 9th New Jersey Symposium on Biomaterials Science and Regenerative Medicine October 29-31, 2008 David H. Sachs, M.D. Harvard Medical

More information

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital

More information

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment

More information

Immunosuppressive therapy in liver transplantation

Immunosuppressive therapy in liver transplantation Journal of Hepatology 39 (2003) 664 678 Short Reviews on Liver Transplantation Associate Editor: Didier Samuel Immunosuppressive therapy in liver transplantation Filomena Conti 1, Emmanuel Morelon 2, Yvon

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (COMMITTEE ABBREVIATION) DRAFT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (COMMITTEE ABBREVIATION) DRAFT European Medicines Agency London, 19 July 2007 Doc. Ref. CHMP/EWP/263148/06 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (COMMITTEE ABBREVIATION) DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF IMMUNOSUPPRESSANTS

More information

American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.

American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant

More information

Summary of Results for Laypersons

Summary of Results for Laypersons What was the Study Called? Summary of Results for Laypersons A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf -/Advagraf -Based Immunosuppressive

More information

Table S1. Clinical outcomes of the acceptable mismatch allocation model.

Table S1. Clinical outcomes of the acceptable mismatch allocation model. Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change

More information

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function

More information

Re: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85)

Re: Final Appraisal Determination - Immunosuppressive therapy for kidney transplant in adults (review of technology appraisal guidance 85) January 19 th, 2016 Dr Margaret Helliwell Vice chair National Institute for Health and Care Excellence 10 Spring Gardens London SW1A 2BU Dear Margaret Re: Final Appraisal Determination - Immunosuppressive

More information

1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo

1980s-1990s1990s 9/24/2010. David Wojciechowski and. Mary Kennedy-Breiner. Laurie Carlson. Janine Sabatte- Caspillo Factors Influencing Length of Stay: 1980s-1990s1990s Mail the Get Well Cards Home!! Effectively Managing Shorter Length of Stays David Wojciechowski and Higher rejection rates Longer duration of induction

More information

Prospective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation

Prospective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation American Journal of Transplantation 2003; 3: 855 864 Copyright # Blackwell Munksgaard 2003 Blackwell Munksgaard ISSN 1600-6135 Prospective, Randomized, Multi-Center Trial of Antibody Therapy in Simultaneous

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors

More information

PRODUCT MONOGRAPH. (basiliximab) 20 mg sterile lyophilized powder for injection/infusion. Immunosuppressant

PRODUCT MONOGRAPH. (basiliximab) 20 mg sterile lyophilized powder for injection/infusion. Immunosuppressant PRODUCT MONOGRAPH Pr SIMULECT (basiliximab) 20 mg sterile lyophilized powder for injection/infusion Immunosuppressant Novartis Pharmaceuticals Canada Inc. 385 Boulevard Bouchard Dorval, Quebec H9S 1A9

More information

Chapter 6: Transplantation

Chapter 6: Transplantation Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

Transplantation. Immunology Unit College of Medicine King Saud University

Transplantation. Immunology Unit College of Medicine King Saud University Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the

More information

Literature Review: Transplantation July 2010-June 2011

Literature Review: Transplantation July 2010-June 2011 Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney

More information

Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation. Alefacept Treatment in the Setting of Transplantation

Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation. Alefacept Treatment in the Setting of Transplantation Trends in Transplant. 2014;8:35-40 Lionel Rostaing, Nassim Kamar: Alefacept and Transplantation Alefacept Treatment in the Setting of Transplantation Lionel Rostaing and Nassim Kamar Department of Nephrology

More information

Rejection after simultaneous pancreas kidney transplantation

Rejection after simultaneous pancreas kidney transplantation Nephrol Dial Transplant (2005) 20 [Suppl 2]: ii11 ii17 doi:10.1093/ndt/gfh1077 Rejection after simultaneous pancreas kidney transplantation Helmut Arbogast 1, Jacques Malaise 3, Wolf-Dieter Illner 1, Anwar

More information

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H. Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 342 M ARCH 2, 2 NUMBER 9 IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES, 1988 TO

More information

CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS

CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS 2018 CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS Revised June 2018 MMF side effects Revised Feb 2018 CMV guideline update Filgrastim/GCSF AMB.03.007 Rev09 Eff Date: 25-June-18 Table of Contents 1. Introduction

More information

Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan

Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan Supporting a Pediatric Investigational Plan for Everolimus - Defining the extrapolation plan Thomas Dumortier, Mick Looby Novartis Pharma AG, Basel, Switzerland EMA public workshop on extrapolation of

More information

Atgam (lymphocyte immune globulin, anti-thymocyte globulin [equine])

Atgam (lymphocyte immune globulin, anti-thymocyte globulin [equine]) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.01 Subject: Atgam Page: 1 of 5 Last Review Date: June 24, 2016 Atgam Description Atgam (lymphocyte

More information

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? American Journal of Transplantation 2017; 17: 22 27 Wiley Periodicals Inc. Minireview 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society

More information

Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R

Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for

More information

BK Virus (BKV) Management Guideline: July 2017

BK Virus (BKV) Management Guideline: July 2017 BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant

More information

The common premise for immunosuppressive

The common premise for immunosuppressive therapy update Current trends in immunosuppressive therapies for renal transplant recipients The common premise for immunosuppressive therapies in kidney transplantation is to use multiple agents to work

More information

Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017

Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Dr AJ Terblanche Paediatric Gastroenterology and Hepatology Unit, SBAH Paediatric Transplant Unit Wits Donald Gordon Medical

More information

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation

More information

Glossary. Anesthesiologist A doctor who puts you or parts of your body to sleep during surgery.

Glossary. Anesthesiologist A doctor who puts you or parts of your body to sleep during surgery. 1-Glossary Glossary Acute rejection A type of rejection that occurs when immune cells from your body attack the transplanted organ(s). Acute rejection may occur at any time after a transplant. But it usually

More information

Heart Transplant: State of the Art. Dr Nick Banner

Heart Transplant: State of the Art. Dr Nick Banner Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Immunopathology of T cell mediated rejection

Immunopathology of T cell mediated rejection Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant

More information

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Disclosure Research Funding from BMS. Learning Objectives -Define belatacept-resistant rejection

More information

North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency

North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.

More information

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2. Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR

More information